REVATIO
®
...
A wEll EsTAblIshEd PdE-5 InhIbITOR REgIsTEREd
fOR usE In PulmOnARy ARTERIAl hyPERTEnsIOn (PAh)
REVATIO
®
helping your patients to do more...
•
Significantly improves exercise capacity (p<0.001)
(1)
•
Significantly reduces mean pulmonary arterial pressure (p=0.04)
(1)
•
Significantly improves physical functioning and general health (p<0.001)
(2)
...without holding them back
•
Convenient oral dosing: 20 mg tds with or without meals
•
Adverse events are generally mild to moderate
(1,3)
•
Low discontinuation rate comparable to placebo
(3)
•
No monthly liver function testing required
(3)
For full prescribing information, refer to the package insert
References: 1.
Galiè N,Ghofrani HA,TorbickiA,Barst RJ,Rubin LJ,Badesch D,
et al
.Sildenafil CitrateTherapy for PulmonaryArterial Hypertension.
N Engl J Med
2005;
353
(20):2148-2157.
2.
Pepke-Zaba J,Gilbert C,Collings L,Brown MCJ.Sildenafil Improves Health-Related Quality
of Life in Patients With Pulmonary Arterial Hypertension.
Chest
2008;
133
:183-189.
3.
Croom KF, Curran MP. Sildenafil.A Review of its Use in Pulmonary Arterial Hypertension.
Drugs
2008;
68
(3):338-397.
S4 REVATIO
®
Film-coated tablets (Reg. No.A40/7.1.5/0131).
COMPOSITION:
Each tablet contains 20 mg of sildenafil, as the citrate.
PHARMACOLOGICAL CLASSIFICATION:
A 7.1.5 Vasodilators – peripheral.
Pfizer Laboratories (Pty) Ltd. Reg. No.: 1954/000781/07. P.O. Box 783720, Sandton 2146.Tel. No.: 0860 PFIZER (734937). PI Ref: 13/07/09. 23/REV/11/10/JA
Start with it, stay with it.
